https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-06-02 / J Clin Oncol 30, 2012 (suppl; abstr 2084)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-06-02 / J Clin Oncol 30, 2012 (suppl; abstr 2084)2012-06-02 12:04:272019-07-17 12:04:49The final report of a phase I trial of surgical resection with biodegradable carmustine (BCNU) wafer placement followed by vaccination with dendritic cells pulsed with tumor lysate for patients with glioblastoma.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-06-02 / J Clin Oncol 30, 2012 (suppl; abstr 2087)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-06-02 / J Clin Oncol 30, 2012 (suppl; abstr 2087)2012-06-02 12:01:292019-07-17 12:01:48Correlation of survival with tumor antigen expression in patients with newly diagnosed glioblastoma receiving a multi-epitope pulsed dendritic cell vaccine.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-06-02 / J Clin Oncol 30, 2012 (suppl; abstr 2525)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-06-02 / J Clin Oncol 30, 2012 (suppl; abstr 2525)2012-06-02 11:40:292019-07-17 11:40:54CD40 ligand/interferon-γ matured DC immunization with gp100 antigen HLA class I A *0201 restricted peptides in patients with newly diagnosed metastatic melanoma.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-06-02 / J Clin Oncol 30, 2012 (suppl; abstr 2524)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-06-02 / J Clin Oncol 30, 2012 (suppl; abstr 2524)2012-06-02 11:39:352019-07-17 11:39:58Adjuvant dendritic cell (DC)-based vaccine therapy of melanoma patients.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-06-01 / J Clin Oncol 30, 2012 (suppl; abstr e15053)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-06-01 / J Clin Oncol 30, 2012 (suppl; abstr e15053)2012-06-01 00:00:002021-08-09 07:54:41Allogeneic partially HLA-matched dendritic cells (DC) as a vaccine in metastatic renal cell cancer (mRCC): Final analysis of a clinical phase I/II study.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-06-01 / Semin. Oncol. 2012 Jun;39(3):287-95
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-06-01 / Semin. Oncol. 2012 Jun;39(3):287-952012-06-01 00:00:002019-02-15 08:39:56Dendritic/tumor fusion cells as cancer vaccines
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-06-01 / Bull Cancer 2012 Jun;99(6):635-42
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-06-01 / Bull Cancer 2012 Jun;99(6):635-422012-06-01 00:00:002019-02-15 08:45:25[Dendritic cell-based therapeutic vaccination for acute myeloid leukemia]
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-05-30 / J. Immunol. Methods 2012 Aug;382(1-2):1-23
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-05-30 / J. Immunol. Methods 2012 Aug;382(1-2):1-232012-05-30 00:00:002019-02-15 08:39:55Cancer therapy and vaccination
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-05-29 / Nat Rev Urol 2012 May;9(7):376-85
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-05-29 / Nat Rev Urol 2012 May;9(7):376-852012-05-29 00:00:002019-02-15 08:53:11Cancer immunotherapy: a paradigm shift for prostate cancer treatment
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-05-29 / Appl. Biochem. Biotechnol. 2012 Aug;167(7):2005-22
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-05-29 / Appl. Biochem. Biotechnol. 2012 Aug;167(7):2005-222012-05-29 00:00:002019-02-15 09:21:30Velogenic newcastle disease virus as an oncolytic virotherapeutics: in vitro characterization
